Press Release For Immediate Release

Glenmark Generics receives final approval from USFDA for Fluticasone propionate 0.05% lotion

May 3, 2011: Glenmark Generics Inc., USA ("Glenmark"), the United States subsidiary of Glenmark Generics Limited, announce they have been granted final approval by the United States Food and Drug Administration (U.S. FDA) for their Abbreviated New Drug Application (ANDA) for fluticasone propionate 0.05% lotion, Glenmark's generic version of Nycomed US ("Nycomed") Cutivate® lotion.

In December 2008, Glenmark confirmed Nycomed filed a patent infringement lawsuit in the U.S. District Court, Eastern District Court of New York, regarding Glenmark's ANDA for fluticasone propionate lotion. The Company believes it is the first applicant to have filed an ANDA for this product with a paragraph IV certification. In the event that Glenmark successfully challenges Nycomed's patent, Glenmark will be entitled to a 180-day exclusivity period.

CUTIVATE® lotion achieved annual sales of approximately USD 48 million in the U.S., based on IMS sales data ending December 2010.

The Company's current portfolio consists of 68 generic products authorized for distribution in the U.S. market, as well as 40 ANDA's filed with the U.S. FDA pending approval. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

About Glenmark Generics Limited.

Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries. It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 63 countries, including the US, various countries in the EU, South America and India.

#####

For further information, please contact:

Jason D'Souza

Glenmark, Mumbai, India Tel: [+91 22] 40189919

Email : connect@glenmark-generics.com